Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Medinotec (MDNC) Cash & Equivalents (2022 - 2025)

Medinotec's Cash & Equivalents history spans 4 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 6.74% year-over-year to $2.9 million; the TTM value through Nov 2025 reached $2.9 million, up 6.74%, while the annual FY2025 figure was $2.8 million, 1.4% down from the prior year.
  • Cash & Equivalents reached $2.9 million in Q4 2025 per MDNC's latest filing, up from $2.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $3.6 million in Q2 2022 to a low of $131577.0 in Q1 2022.
  • Average Cash & Equivalents over 4 years is $2.6 million, with a median of $2.8 million recorded in 2024.
  • The largest YoY upside for Cash & Equivalents was 2048.9% in 2023 against a maximum downside of 23.93% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $2.8 million in 2022, then decreased by 5.9% to $2.7 million in 2023, then decreased by 0.08% to $2.7 million in 2024, then increased by 6.74% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for MDNC's Cash & Equivalents are $2.9 million (Q4 2025), $2.2 million (Q3 2025), and $2.0 million (Q2 2025).